SCLC transformation from NSCLC has rarely been observed in EGFR-wild type lung cancers or during ALK-targeted therapy and programed cell death-1 (PD-1/L)-directed immunotherapy[31]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.